Decreased expression of SELENBP1 could promote tumor invasiveness by increasing GPX1 activity and diminishing hypoxia-inducible protein-1alpha (HIF-1α, a tumor suppressor) expression in HCC; SELENBP1 could be a novel biomarker for predicting prognosis and guiding personalized therapeutic strategies, especially in patients with advanced HCC (Huang et al., 2012). The gene discussed is SELENBP1; the disease is hepatocellular carcinoma.